^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | nesuparib (JPI-547) (PARP inhibitor, TNKS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
Excerpt:
...confirmed BRCA1/2 mutation *** or HRD ****...
Trial ID:
Source:
Title:
4485 / 10 - JPI-547, a novel dual inhibitor of PARP 1/2 and tankyrase 1/2 overcomes olaparib resistance in BRCA 1/2 mutant ovary and breast cancer preclinical model
Published date:
03/15/2023
Excerpt:
An olaparib-resistant PDTX model [WJO-003(O2)], the parent BRCA1 mutation carrying ovary cancer PDTX was engrafted and treated with olaparib in 75mg/kg twice daily for 1 month and then 100mg/kg twice daily for 3 months....In the olaparib-resistant PDTX model, WJO-003(O2), JPI-547 inhibited tumor growth the most effectively compared to other PARP inhibitors (at day 60, the mean tumor volume: 2539, 1319, 871, 601, and 29 mm3 in control, niraparib, olaparib, talazoparib, and JPI-547, respectively; p<0.01).
